Clinical trial · Observational
The Effectiveness and Tolerability of Fentanyl Matrix in Chronic Non-cancer Pain; Assessment of Patient's Pain Treatment Goal Achievement
The Effectiveness and Tolerability of Fentanyl Matrix in Chronic Non-cancer Pain; Assessment of Patient's Pain Treatment Goal Achievement: Multicenter, Prospective, Open-label, Observational Study
NCT01688583CI-TRIAL-00012702completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to assess the effectiveness and tolerability of Fentanyl matrix in chronic non-cancer pain.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Pain | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Fentanyl matrix | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Fentanyl matrix
- interventionNames
- Drug: Fentanyl matrix
Primary outcomes (1)
- measure
- The percentage of patients with mean % Pain Intensity Difference (%PID) >= 50% from baseline to endpoint
- timeFrame
- 12 weeks
- description
- Pain intensity will be measured using a numeric rating scale (NRS), from 0 (no pain) to 10 (worst pain imaginable).
Secondary outcomes (7)
- measure
- The change from baseline in mean pain intensity
- timeFrame
- Baseline, Week 12
- description
- Pain intensity will be measured using a numeric rating scale (NRS), from 0 (no pain) to 10 (worst pain imaginable).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Complain of chronic non-cancer pain that persists for \>= 3 months * Pain inadequately controlled by previous treatment with narcotic analgesics (opium or opium-like compounds with potent analgesic effects, eg, tramadol, codeine, morphine, oxycodone) * Women must be postmenopausal, surgically sterile, abstinent, or practicing an effective method of birth control if they have childbearing potential * Male patients who agree to use a method of birth control and not to donate sperm for 1 month after the last dose of the study drug * A written informed consent for study participation Exclusion Criteria: * Experience of treatment with Fentanyl matrix within the past 4 weeks * No previous experience of use of narcotic analgesics * Past or current history of alcohol or drug abuse * Cannot use transdermal analgesics due to skin disorder * Have serious psychiatric disorder and cannot complete overall study procedures and questionnaire in the judgment of the investigator
References
Publications (0)
Data not yet available
No reference posted for this study.